Story perspectives

Trump Pushes Fast-Track Psychedelics, $50M Funding, Vouchers

4/25/2026

Summary

Story summary

President Donald Trump’s executive order directs the FDA to fast-track psychedelic drugs with breakthrough-therapy status and allocates $50 million for state research.
The FDA granted national priority vouchers to Compass Pathways, the Usona Institute and Transcend Therapeutics to cut review to one-to-two months without lowering standards.
The Psychedelic Medicine Coalition says faster approvals could spur insurance coverage, training and credentialing, while the American Psychiatric Association urges rigorous data and patient protections.

1 of 1

Story summary

President Donald Trump’s executive order directs the FDA to fast-track psychedelic drugs with breakthrough-therapy status and allocates $50 million for state research.
The FDA granted national priority vouchers to Compass Pathways, the Usona Institute and Transcend Therapeutics to cut review to one-to-two months without lowering standards.
The Psychedelic Medicine Coalition says faster approvals could spur insurance coverage, training and credentialing, while the American Psychiatric Association urges rigorous data and patient protections.